RP 3128

Drug Profile

RP 3128

Alternative Names: RP3128

Latest Information Update: 04 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Rhizen Pharmaceuticals
  • Class Antiasthmatics; Small molecules
  • Mechanism of Action Calcium channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Asthma

Most Recent Events

  • 21 Mar 2018 Rhizen Pharmaceuticals terminates a phase I/II trial due to significant recruitment delay in POC part in Asthma in Canada (PO) (NCT02958982)
  • 01 Oct 2016 Phase-I/II clinical trials in Asthma in Canada (PO) (NCT02958982)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top